nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—SLC22A2—Cytarabine—lymphatic system cancer	0.144	0.192	CbGbCtD
Imipramine—SLC22A1—Cytarabine—lymphatic system cancer	0.125	0.167	CbGbCtD
Imipramine—SLC22A3—Vincristine—lymphatic system cancer	0.115	0.154	CbGbCtD
Imipramine—CYP1A2—Carmustine—lymphatic system cancer	0.0641	0.0857	CbGbCtD
Imipramine—CYP2E1—Mitoxantrone—lymphatic system cancer	0.0521	0.0696	CbGbCtD
Imipramine—CYP2C19—Teniposide—lymphatic system cancer	0.0467	0.0624	CbGbCtD
Imipramine—CYP3A7—Vincristine—lymphatic system cancer	0.0372	0.0496	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0372	0.0496	CbGbCtD
Imipramine—ABCB1—Mitoxantrone—lymphatic system cancer	0.0264	0.0352	CbGbCtD
Imipramine—CYP3A4—Cytarabine—lymphatic system cancer	0.0229	0.0306	CbGbCtD
Imipramine—CYP3A4—Teniposide—lymphatic system cancer	0.0226	0.0302	CbGbCtD
Imipramine—ABCB1—Vincristine—lymphatic system cancer	0.0181	0.0242	CbGbCtD
Imipramine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0158	0.0211	CbGbCtD
Imipramine—ABCB1—Methotrexate—lymphatic system cancer	0.011	0.0147	CbGbCtD
Imipramine—CYP3A4—Vincristine—lymphatic system cancer	0.0109	0.0145	CbGbCtD
Imipramine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000661	0.00263	CcSEcCtD
Imipramine—Speech disorder—Methotrexate—lymphatic system cancer	0.000661	0.00263	CcSEcCtD
Imipramine—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.000659	0.00262	CcSEcCtD
Imipramine—Flushing—Bleomycin—lymphatic system cancer	0.000655	0.00261	CcSEcCtD
Imipramine—Anorexia—Fludarabine—lymphatic system cancer	0.000652	0.0026	CcSEcCtD
Imipramine—Weight increased—Mitoxantrone—lymphatic system cancer	0.000651	0.00259	CcSEcCtD
Imipramine—Weight decreased—Mitoxantrone—lymphatic system cancer	0.000647	0.00258	CcSEcCtD
Imipramine—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000646	0.00257	CcSEcCtD
Imipramine—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.000642	0.00256	CcSEcCtD
Imipramine—Myocardial infarction—Vincristine—lymphatic system cancer	0.000642	0.00256	CcSEcCtD
Imipramine—Feeling abnormal—Teniposide—lymphatic system cancer	0.000641	0.00255	CcSEcCtD
Imipramine—Stomatitis—Vincristine—lymphatic system cancer	0.000639	0.00254	CcSEcCtD
Imipramine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.000638	0.00254	CcSEcCtD
Imipramine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000636	0.00253	CcSEcCtD
Imipramine—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000629	0.0025	CcSEcCtD
Imipramine—Nausea—Mechlorethamine—lymphatic system cancer	0.000627	0.0025	CcSEcCtD
Imipramine—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000625	0.00249	CcSEcCtD
Imipramine—Alopecia—Bleomycin—lymphatic system cancer	0.000624	0.00248	CcSEcCtD
Imipramine—Stomatitis—Mitoxantrone—lymphatic system cancer	0.000622	0.00248	CcSEcCtD
Imipramine—Jaundice—Mitoxantrone—lymphatic system cancer	0.000622	0.00248	CcSEcCtD
Imipramine—Urticaria—Teniposide—lymphatic system cancer	0.000618	0.00246	CcSEcCtD
Imipramine—Abdominal pain—Teniposide—lymphatic system cancer	0.000615	0.00245	CcSEcCtD
Imipramine—Body temperature increased—Teniposide—lymphatic system cancer	0.000615	0.00245	CcSEcCtD
Imipramine—Paraesthesia—Fludarabine—lymphatic system cancer	0.000614	0.00244	CcSEcCtD
Imipramine—Hallucination—Carmustine—lymphatic system cancer	0.000613	0.00244	CcSEcCtD
Imipramine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000613	0.00244	CcSEcCtD
Imipramine—Dyspepsia—Fludarabine—lymphatic system cancer	0.000602	0.0024	CcSEcCtD
Imipramine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000595	0.00237	CcSEcCtD
Imipramine—Decreased appetite—Fludarabine—lymphatic system cancer	0.000595	0.00237	CcSEcCtD
Imipramine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00059	0.00235	CcSEcCtD
Imipramine—Fatigue—Fludarabine—lymphatic system cancer	0.00059	0.00235	CcSEcCtD
Imipramine—Hallucination—Vincristine—lymphatic system cancer	0.000585	0.00233	CcSEcCtD
Imipramine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000585	0.00233	CcSEcCtD
Imipramine—Constipation—Fludarabine—lymphatic system cancer	0.000585	0.00233	CcSEcCtD
Imipramine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000581	0.00231	CcSEcCtD
Imipramine—Urethral disorder—Vincristine—lymphatic system cancer	0.000577	0.0023	CcSEcCtD
Imipramine—Eye disorder—Carmustine—lymphatic system cancer	0.000576	0.00229	CcSEcCtD
Imipramine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000573	0.00228	CcSEcCtD
Imipramine—Flushing—Carmustine—lymphatic system cancer	0.000572	0.00228	CcSEcCtD
Imipramine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00057	0.00227	CcSEcCtD
Imipramine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000564	0.00224	CcSEcCtD
Imipramine—Asthenia—Teniposide—lymphatic system cancer	0.000558	0.00222	CcSEcCtD
Imipramine—Malaise—Bleomycin—lymphatic system cancer	0.000554	0.00221	CcSEcCtD
Imipramine—Pruritus—Teniposide—lymphatic system cancer	0.000551	0.00219	CcSEcCtD
Imipramine—Arrhythmia—Carmustine—lymphatic system cancer	0.00055	0.00219	CcSEcCtD
Imipramine—Leukopenia—Bleomycin—lymphatic system cancer	0.00055	0.00219	CcSEcCtD
Imipramine—Cardiac disorder—Vincristine—lymphatic system cancer	0.000546	0.00217	CcSEcCtD
Imipramine—Alopecia—Carmustine—lymphatic system cancer	0.000544	0.00217	CcSEcCtD
Imipramine—Body temperature increased—Fludarabine—lymphatic system cancer	0.000541	0.00215	CcSEcCtD
Imipramine—Mental disorder—Carmustine—lymphatic system cancer	0.00054	0.00215	CcSEcCtD
Imipramine—Malnutrition—Carmustine—lymphatic system cancer	0.000536	0.00214	CcSEcCtD
Imipramine—Angiopathy—Vincristine—lymphatic system cancer	0.000534	0.00212	CcSEcCtD
Imipramine—Diarrhoea—Teniposide—lymphatic system cancer	0.000532	0.00212	CcSEcCtD
Imipramine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00053	0.00211	CcSEcCtD
Imipramine—Alopecia—Vincristine—lymphatic system cancer	0.00052	0.00207	CcSEcCtD
Imipramine—Discomfort—Bleomycin—lymphatic system cancer	0.000517	0.00206	CcSEcCtD
Imipramine—Mental disorder—Vincristine—lymphatic system cancer	0.000515	0.00205	CcSEcCtD
Imipramine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000512	0.00204	CcSEcCtD
Imipramine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000508	0.00202	CcSEcCtD
Imipramine—Alopecia—Mitoxantrone—lymphatic system cancer	0.000506	0.00201	CcSEcCtD
Imipramine—Confusional state—Bleomycin—lymphatic system cancer	0.000506	0.00201	CcSEcCtD
Imipramine—Vision blurred—Carmustine—lymphatic system cancer	0.000505	0.00201	CcSEcCtD
Imipramine—Tremor—Carmustine—lymphatic system cancer	0.000502	0.002	CcSEcCtD
Imipramine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000501	0.002	CcSEcCtD
Imipramine—Oedema—Bleomycin—lymphatic system cancer	0.000501	0.002	CcSEcCtD
Imipramine—Infection—Bleomycin—lymphatic system cancer	0.000498	0.00198	CcSEcCtD
Imipramine—Vomiting—Teniposide—lymphatic system cancer	0.000495	0.00197	CcSEcCtD
Imipramine—Agitation—Carmustine—lymphatic system cancer	0.000493	0.00196	CcSEcCtD
Imipramine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000491	0.00195	CcSEcCtD
Imipramine—Asthenia—Fludarabine—lymphatic system cancer	0.000491	0.00195	CcSEcCtD
Imipramine—Rash—Teniposide—lymphatic system cancer	0.000491	0.00195	CcSEcCtD
Imipramine—Dermatitis—Teniposide—lymphatic system cancer	0.00049	0.00195	CcSEcCtD
Imipramine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000488	0.00194	CcSEcCtD
Imipramine—Headache—Teniposide—lymphatic system cancer	0.000487	0.00194	CcSEcCtD
Imipramine—Pruritus—Fludarabine—lymphatic system cancer	0.000484	0.00193	CcSEcCtD
Imipramine—Leukopenia—Carmustine—lymphatic system cancer	0.00048	0.00191	CcSEcCtD
Imipramine—Anorexia—Bleomycin—lymphatic system cancer	0.000478	0.0019	CcSEcCtD
Imipramine—Agitation—Vincristine—lymphatic system cancer	0.00047	0.00187	CcSEcCtD
Imipramine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00047	0.00187	CcSEcCtD
Imipramine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000468	0.00186	CcSEcCtD
Imipramine—Convulsion—Carmustine—lymphatic system cancer	0.000465	0.00185	CcSEcCtD
Imipramine—Hypertension—Carmustine—lymphatic system cancer	0.000463	0.00184	CcSEcCtD
Imipramine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000463	0.00184	CcSEcCtD
Imipramine—Nausea—Teniposide—lymphatic system cancer	0.000462	0.00184	CcSEcCtD
Imipramine—Leukopenia—Vincristine—lymphatic system cancer	0.000458	0.00182	CcSEcCtD
Imipramine—Anxiety—Carmustine—lymphatic system cancer	0.000455	0.00181	CcSEcCtD
Imipramine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00045	0.00179	CcSEcCtD
Imipramine—Malaise—Mitoxantrone—lymphatic system cancer	0.00045	0.00179	CcSEcCtD
Imipramine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000446	0.00178	CcSEcCtD
Imipramine—Convulsion—Vincristine—lymphatic system cancer	0.000444	0.00177	CcSEcCtD
Imipramine—Hypertension—Vincristine—lymphatic system cancer	0.000442	0.00176	CcSEcCtD
Imipramine—Confusional state—Carmustine—lymphatic system cancer	0.000441	0.00176	CcSEcCtD
Imipramine—Oedema—Carmustine—lymphatic system cancer	0.000438	0.00174	CcSEcCtD
Imipramine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000436	0.00174	CcSEcCtD
Imipramine—Infection—Carmustine—lymphatic system cancer	0.000435	0.00173	CcSEcCtD
Imipramine—Vomiting—Fludarabine—lymphatic system cancer	0.000435	0.00173	CcSEcCtD
Imipramine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000432	0.00172	CcSEcCtD
Imipramine—Rash—Fludarabine—lymphatic system cancer	0.000431	0.00172	CcSEcCtD
Imipramine—Dermatitis—Fludarabine—lymphatic system cancer	0.000431	0.00172	CcSEcCtD
Imipramine—Hypertension—Mitoxantrone—lymphatic system cancer	0.00043	0.00171	CcSEcCtD
Imipramine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000429	0.00171	CcSEcCtD
Imipramine—Headache—Fludarabine—lymphatic system cancer	0.000428	0.00171	CcSEcCtD
Imipramine—Tachycardia—Carmustine—lymphatic system cancer	0.000427	0.0017	CcSEcCtD
Imipramine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000423	0.00168	CcSEcCtD
Imipramine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000421	0.00168	CcSEcCtD
Imipramine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000419	0.00167	CcSEcCtD
Imipramine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000418	0.00166	CcSEcCtD
Imipramine—Oedema—Vincristine—lymphatic system cancer	0.000418	0.00166	CcSEcCtD
Imipramine—Anorexia—Carmustine—lymphatic system cancer	0.000417	0.00166	CcSEcCtD
Imipramine—Infection—Vincristine—lymphatic system cancer	0.000415	0.00165	CcSEcCtD
Imipramine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000413	0.00165	CcSEcCtD
Imipramine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00041	0.00163	CcSEcCtD
Imipramine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00041	0.00163	CcSEcCtD
Imipramine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000409	0.00163	CcSEcCtD
Imipramine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000407	0.00162	CcSEcCtD
Imipramine—Oedema—Mitoxantrone—lymphatic system cancer	0.000407	0.00162	CcSEcCtD
Imipramine—Nausea—Fludarabine—lymphatic system cancer	0.000406	0.00162	CcSEcCtD
Imipramine—Infection—Mitoxantrone—lymphatic system cancer	0.000404	0.00161	CcSEcCtD
Imipramine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000404	0.00161	CcSEcCtD
Imipramine—Shock—Mitoxantrone—lymphatic system cancer	0.0004	0.00159	CcSEcCtD
Imipramine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000398	0.00159	CcSEcCtD
Imipramine—Urticaria—Bleomycin—lymphatic system cancer	0.000398	0.00159	CcSEcCtD
Imipramine—Anorexia—Vincristine—lymphatic system cancer	0.000398	0.00159	CcSEcCtD
Imipramine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000397	0.00158	CcSEcCtD
Imipramine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000396	0.00158	CcSEcCtD
Imipramine—Insomnia—Carmustine—lymphatic system cancer	0.000396	0.00158	CcSEcCtD
Imipramine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000395	0.00157	CcSEcCtD
Imipramine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000393	0.00157	CcSEcCtD
Imipramine—Paraesthesia—Carmustine—lymphatic system cancer	0.000393	0.00156	CcSEcCtD
Imipramine—Mood swings—Methotrexate—lymphatic system cancer	0.000391	0.00156	CcSEcCtD
Imipramine—Somnolence—Carmustine—lymphatic system cancer	0.000389	0.00155	CcSEcCtD
Imipramine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000388	0.00154	CcSEcCtD
Imipramine—Ataxia—Methotrexate—lymphatic system cancer	0.000388	0.00154	CcSEcCtD
Imipramine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000381	0.00152	CcSEcCtD
Imipramine—Decreased appetite—Carmustine—lymphatic system cancer	0.00038	0.00151	CcSEcCtD
Imipramine—Insomnia—Vincristine—lymphatic system cancer	0.000378	0.0015	CcSEcCtD
Imipramine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000378	0.0015	CcSEcCtD
Imipramine—Paraesthesia—Vincristine—lymphatic system cancer	0.000375	0.00149	CcSEcCtD
Imipramine—Constipation—Carmustine—lymphatic system cancer	0.000374	0.00149	CcSEcCtD
Imipramine—Breast disorder—Methotrexate—lymphatic system cancer	0.000373	0.00148	CcSEcCtD
Imipramine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000365	0.00145	CcSEcCtD
Imipramine—Decreased appetite—Vincristine—lymphatic system cancer	0.000363	0.00145	CcSEcCtD
Imipramine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000362	0.00144	CcSEcCtD
Imipramine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000361	0.00144	CcSEcCtD
Imipramine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000361	0.00144	CcSEcCtD
Imipramine—Fatigue—Vincristine—lymphatic system cancer	0.00036	0.00143	CcSEcCtD
Imipramine—Asthenia—Bleomycin—lymphatic system cancer	0.00036	0.00143	CcSEcCtD
Imipramine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000358	0.00143	CcSEcCtD
Imipramine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000358	0.00142	CcSEcCtD
Imipramine—Constipation—Vincristine—lymphatic system cancer	0.000357	0.00142	CcSEcCtD
Imipramine—Pruritus—Bleomycin—lymphatic system cancer	0.000355	0.00141	CcSEcCtD
Imipramine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000354	0.00141	CcSEcCtD
Imipramine—Eosinophilia—Methotrexate—lymphatic system cancer	0.000353	0.00141	CcSEcCtD
Imipramine—Fatigue—Mitoxantrone—lymphatic system cancer	0.000351	0.0014	CcSEcCtD
Imipramine—Constipation—Mitoxantrone—lymphatic system cancer	0.000348	0.00139	CcSEcCtD
Imipramine—Abdominal pain—Carmustine—lymphatic system cancer	0.000346	0.00138	CcSEcCtD
Imipramine—Body temperature increased—Carmustine—lymphatic system cancer	0.000346	0.00138	CcSEcCtD
Imipramine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000342	0.00136	CcSEcCtD
Imipramine—Pancytopenia—Methotrexate—lymphatic system cancer	0.000339	0.00135	CcSEcCtD
Imipramine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000335	0.00133	CcSEcCtD
Imipramine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000333	0.00132	CcSEcCtD
Imipramine—Abdominal pain—Vincristine—lymphatic system cancer	0.00033	0.00131	CcSEcCtD
Imipramine—Body temperature increased—Vincristine—lymphatic system cancer	0.00033	0.00131	CcSEcCtD
Imipramine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000328	0.00131	CcSEcCtD
Imipramine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000325	0.0013	CcSEcCtD
Imipramine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000323	0.00129	CcSEcCtD
Imipramine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000322	0.00128	CcSEcCtD
Imipramine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000322	0.00128	CcSEcCtD
Imipramine—Vomiting—Bleomycin—lymphatic system cancer	0.000319	0.00127	CcSEcCtD
Imipramine—Infestation—Methotrexate—lymphatic system cancer	0.000318	0.00127	CcSEcCtD
Imipramine—Infestation NOS—Methotrexate—lymphatic system cancer	0.000318	0.00127	CcSEcCtD
Imipramine—Drowsiness—Methotrexate—lymphatic system cancer	0.000318	0.00127	CcSEcCtD
Imipramine—Rash—Bleomycin—lymphatic system cancer	0.000316	0.00126	CcSEcCtD
Imipramine—Dermatitis—Bleomycin—lymphatic system cancer	0.000316	0.00126	CcSEcCtD
Imipramine—Asthenia—Carmustine—lymphatic system cancer	0.000314	0.00125	CcSEcCtD
Imipramine—Stomatitis—Methotrexate—lymphatic system cancer	0.00031	0.00123	CcSEcCtD
Imipramine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000301	0.0012	CcSEcCtD
Imipramine—Asthenia—Vincristine—lymphatic system cancer	0.0003	0.00119	CcSEcCtD
Imipramine—Diarrhoea—Carmustine—lymphatic system cancer	0.000299	0.00119	CcSEcCtD
Imipramine—Nausea—Bleomycin—lymphatic system cancer	0.000298	0.00119	CcSEcCtD
Imipramine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000297	0.00118	CcSEcCtD
Imipramine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000292	0.00116	CcSEcCtD
Imipramine—Dizziness—Carmustine—lymphatic system cancer	0.000289	0.00115	CcSEcCtD
Imipramine—Diarrhoea—Vincristine—lymphatic system cancer	0.000286	0.00114	CcSEcCtD
Imipramine—Hepatitis—Methotrexate—lymphatic system cancer	0.000285	0.00114	CcSEcCtD
Imipramine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000282	0.00112	CcSEcCtD
Imipramine—Urethral disorder—Methotrexate—lymphatic system cancer	0.00028	0.00111	CcSEcCtD
Imipramine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000278	0.00111	CcSEcCtD
Imipramine—Vomiting—Carmustine—lymphatic system cancer	0.000278	0.00111	CcSEcCtD
Imipramine—Dizziness—Vincristine—lymphatic system cancer	0.000276	0.0011	CcSEcCtD
Imipramine—Rash—Carmustine—lymphatic system cancer	0.000276	0.0011	CcSEcCtD
Imipramine—Dermatitis—Carmustine—lymphatic system cancer	0.000276	0.0011	CcSEcCtD
Imipramine—Headache—Carmustine—lymphatic system cancer	0.000274	0.00109	CcSEcCtD
Imipramine—Eye disorder—Methotrexate—lymphatic system cancer	0.000267	0.00106	CcSEcCtD
Imipramine—Tinnitus—Methotrexate—lymphatic system cancer	0.000266	0.00106	CcSEcCtD
Imipramine—Vomiting—Vincristine—lymphatic system cancer	0.000266	0.00106	CcSEcCtD
Imipramine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000265	0.00105	CcSEcCtD
Imipramine—Rash—Vincristine—lymphatic system cancer	0.000263	0.00105	CcSEcCtD
Imipramine—Dermatitis—Vincristine—lymphatic system cancer	0.000263	0.00105	CcSEcCtD
Imipramine—Headache—Vincristine—lymphatic system cancer	0.000262	0.00104	CcSEcCtD
Imipramine—Nausea—Carmustine—lymphatic system cancer	0.00026	0.00104	CcSEcCtD
Imipramine—Angiopathy—Methotrexate—lymphatic system cancer	0.000259	0.00103	CcSEcCtD
Imipramine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000259	0.00103	CcSEcCtD
Imipramine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000258	0.00103	CcSEcCtD
Imipramine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000257	0.00102	CcSEcCtD
Imipramine—Rash—Mitoxantrone—lymphatic system cancer	0.000257	0.00102	CcSEcCtD
Imipramine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000256	0.00102	CcSEcCtD
Imipramine—Headache—Mitoxantrone—lymphatic system cancer	0.000255	0.00101	CcSEcCtD
Imipramine—Alopecia—Methotrexate—lymphatic system cancer	0.000252	0.001	CcSEcCtD
Imipramine—Mental disorder—Methotrexate—lymphatic system cancer	0.00025	0.000995	CcSEcCtD
Imipramine—Malnutrition—Methotrexate—lymphatic system cancer	0.000248	0.000989	CcSEcCtD
Imipramine—Nausea—Vincristine—lymphatic system cancer	0.000248	0.000988	CcSEcCtD
Imipramine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000243	0.000968	CcSEcCtD
Imipramine—Nausea—Mitoxantrone—lymphatic system cancer	0.000242	0.000962	CcSEcCtD
Imipramine—Vision blurred—Methotrexate—lymphatic system cancer	0.000234	0.000932	CcSEcCtD
Imipramine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00023	0.000918	CcSEcCtD
Imipramine—Malaise—Methotrexate—lymphatic system cancer	0.000224	0.000892	CcSEcCtD
Imipramine—Leukopenia—Methotrexate—lymphatic system cancer	0.000222	0.000885	CcSEcCtD
Imipramine—Convulsion—Methotrexate—lymphatic system cancer	0.000215	0.000857	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00021	0.000836	CcSEcCtD
Imipramine—Discomfort—Methotrexate—lymphatic system cancer	0.000209	0.000832	CcSEcCtD
Imipramine—Confusional state—Methotrexate—lymphatic system cancer	0.000204	0.000814	CcSEcCtD
Imipramine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000203	0.000807	CcSEcCtD
Imipramine—Infection—Methotrexate—lymphatic system cancer	0.000201	0.000802	CcSEcCtD
Imipramine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000199	0.000792	CcSEcCtD
Imipramine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000199	0.00079	CcSEcCtD
Imipramine—Skin disorder—Methotrexate—lymphatic system cancer	0.000197	0.000784	CcSEcCtD
Imipramine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000196	0.00078	CcSEcCtD
Imipramine—Anorexia—Methotrexate—lymphatic system cancer	0.000193	0.000769	CcSEcCtD
Imipramine—Insomnia—Methotrexate—lymphatic system cancer	0.000183	0.00073	CcSEcCtD
Imipramine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000182	0.000725	CcSEcCtD
Imipramine—Somnolence—Methotrexate—lymphatic system cancer	0.00018	0.000718	CcSEcCtD
Imipramine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000178	0.00071	CcSEcCtD
Imipramine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000176	0.000702	CcSEcCtD
Imipramine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000175	0.000697	CcSEcCtD
Imipramine—Fatigue—Methotrexate—lymphatic system cancer	0.000175	0.000696	CcSEcCtD
Imipramine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000167	0.000665	CcSEcCtD
Imipramine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000166	0.00066	CcSEcCtD
Imipramine—Urticaria—Methotrexate—lymphatic system cancer	0.000161	0.000641	CcSEcCtD
Imipramine—Abdominal pain—Methotrexate—lymphatic system cancer	0.00016	0.000638	CcSEcCtD
Imipramine—Body temperature increased—Methotrexate—lymphatic system cancer	0.00016	0.000638	CcSEcCtD
Imipramine—Asthenia—Methotrexate—lymphatic system cancer	0.000145	0.000579	CcSEcCtD
Imipramine—Pruritus—Methotrexate—lymphatic system cancer	0.000143	0.000571	CcSEcCtD
Imipramine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000139	0.000552	CcSEcCtD
Imipramine—Dizziness—Methotrexate—lymphatic system cancer	0.000134	0.000534	CcSEcCtD
Imipramine—Vomiting—Methotrexate—lymphatic system cancer	0.000129	0.000513	CcSEcCtD
Imipramine—Rash—Methotrexate—lymphatic system cancer	0.000128	0.000509	CcSEcCtD
Imipramine—Dermatitis—Methotrexate—lymphatic system cancer	0.000128	0.000508	CcSEcCtD
Imipramine—Headache—Methotrexate—lymphatic system cancer	0.000127	0.000506	CcSEcCtD
Imipramine—Nausea—Methotrexate—lymphatic system cancer	0.00012	0.000479	CcSEcCtD
